CellBion Co., Ltd. (KOSDAQ:308430)

Market Cap	324.00B +94.1%
Revenue (ttm)	2.13B -2.4%
Net Income	-7.55B
EPS	-589.39
Shares Out	12.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	119,350
Average Volume	149,268
Open	24,850
Previous Close	25,500
Day's Range	23,900 - 26,000
52-Week Range	14,420 - 29,600
Beta	n/a
RSI	57.07
Earnings Date	Mar 30, 2026

About CellBion

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 99mTc-MSA-ICG, indicated for lymphoscintigraphy SLN mapping, currently under Phase 1 clinical stage; and 68Ga-NGUL, indicated for prostate ...

• Industry: Pharmaceutical Preparations
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 308430

Financial Performance

In 2024, CellBion's revenue was 2.29 billion, an increase of 55.64% compared to the previous year's 1.47 billion. Losses were -7.27 billion, 100.0% more than in 2023.